Fly News Breaks for January 10, 2020
Jan 10, 2020 | 07:36 EDT
Cowen analyst Phil Nadeau lowered his price target on Portola Pharmaceuticals to $35 from $45 after the company preannounced its Q4 sales of Andexxa which was significantly below consensus. The analyst said the decline was caused by a reduction in utilization at early adopting Tier-1 hospitals following drug utilization reviews. Nadeau maintained his Outperform rating on Portola Pharmaceuticals shares.
News For PTLA From the Last 2 Days
There are no results for your query PTLA